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CARMA2sh and ULK2 control pathogen-associated
molecular patterns recognition in human keratinocytes:
psoriasis-linked CARMA2sh mutants escape ULK2
censorship
Ivan Scudiero*,1, Pellegrino Mazzone1, Luca E D’Andrea1, Angela Ferravante1, Tiziana Zotti2, Gianluca Telesio1, Gabriele De Rubis1,
Carla Reale1, Maddalena Pizzulo1, Shanmugakonar Muralitharan3, Pasquale Vito*,1,4 and Romania Stilo1,4
The molecular complexes formed by specific members of the family of CARMA proteins, the CARD domain-containing adapter
molecule BCL10 and MALT1 (CBM complex) represent a central hub in regulating activation of the pleiotropic transcription factor
NF-κB. Recently, missense mutations in CARMA2sh have been shown to cause psoriasis in a dominant manner and with high
penetrancy. Here, we demonstrate that in human keratinocytes CARMA2sh plays an essential role in the signal transduction
pathway that connects pathogen-associated molecular patterns recognition to NF-κB activation. We also find that the serine/
threonine kinase ULK2 binds to and phosphorylates CARMA2sh, thereby inhibiting its capacity to activate NF-κB by promoting
lysosomal degradation of BCL10, which is essential for CARMA2sh-mediated NF-κB signaling. Remarkably, CARMA2sh mutants
associated with psoriasis escape ULK2 inhibition. Finally, we show that a peptide blocking CARD-mediated BCL10 interactions
reduces the capacity of psoriasis-linked CARMA2sh mutants to activate NF-κB. Our work elucidates a fundamental signaling
mechanism operating in human keratinocytes and opens to novel potential tools for the therapeutical treatment of human skin
disorders.
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Psoriasis is a debilitating skin disease affecting ~ 2–3% of
human population.1 The disease is considered to have key
genetic underpinnings, and genome-wide association studies
and meta-analysis have identified more than 40 susceptibility
loci for psoriasis.1–5 Recently, missense mutations in the
CARD14/CARMA2/Bimp2 (CARMA2) gene products have
been shown to dominantly transmit the psoriatic trait with
high penetrancy.6–8 Mutations in CARMA2 are also found in
individuals affected by familial pityriasis rubra pilaris (PRP), a
skin disorder phenotypically related to psoriasis.9 When
introduced in CARMA2sh, the prominent CARMA2 isoform
expressed in the human skin,7,10,11 most CARMA2 mutations
associated with psoriasis and PRP cause a deregulated,
enhanced activity of NF-κB, a transcription factor that
catalyzes expression of inflammatory genes.6,7,9,10 Indeed,
similarly to classic psoriasis, transcriptomes of psoriatic
patients carrying mutations in CARMA2 are significantly
enriched in transcripts functioning in inflammatory pathways
including the LPS/IL-1 pathways.10 CARMA2sh activates
NF-κB through assembly of the CARMA/BCL10/MALT1
(CBM) complex, a molecular complex that in addition to
CARMA2sh also includes the paracaspase MALT1 and the
adapter molecule BCL10.11–13 BCL10 is a critical mediator of
NF-κB activation in immune cells, and genetic deficiency of
BCL10 results in combined immunodeficiency in both humans
and mice, due to impaired NF-κB activation following antigen
receptor stimulation.14–16 In addition, in lymphoid cells
selective degradation of BCL10 represents an homeostatic
mechanism that prevents unrestrained NF-κB signaling.17–19
More recent reports have also identified BCL10 as a positive
regulator of inflammatory cascades in non-immune cells,
including the LPS-toll-like receptor (TLR)4-induced pathway of
NF-κB activation.20–22 Here, we find that the serine/threonine
kinase ULK2 binds to and phosphorylates CARMA2sh,
thereby inhibiting its capacity to activate NF-κB by promoting
lysosomal degradation of BCL10. Remarkably, CARMA2sh
mutants associated with psoriasis escape ULK2 inhibition. We
also show that in human keratinocytes the CBM complex plays
an essential role in the signal transduction pathway that links
pathogen-associated molecular patterns (PAMPs) recognition
on the cell membrane to NF-κB activation.
Results
ULK2 binds to and phosphorylates CARMA2sh. Most of
the studies conducted to elucidate the functional role of
CARMA2 and its mutated forms associated with psoriasis
have been carried out using CARMA2sh,6–9,11 the prominent
isoform of CARMA2 expressed in the human skin.7,10 Thus,
to search for functional regulators of CARMA2sh we
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performed a yeast two-hybrid screen using as a bait
CARMA2sh fused to the GAL4 DNA-binding domain. A total
of 14 yeast clones were isolated that activated the β-galacto-
sidase reporter gene when ~ 2× 106 library plasmids
were screened. Sequence analysis of these CARMA2sh
putative interactors revealed that one isolated plasmid enco-
ded for amino acids Leu805–Val1036 of ULK2, a serine/threo-
nine kinase involved in autophagy.23,24 As summarized in
Table 1, this library clone did not activate the yeast GAL4-
reporter genes by itself or when co-expressed with the empty
GAL4BD vector, or with a control plasmid. Conversely, it
strongly interacted with GAL4BD-CARMA2sh fusion protein.
Interaction between CARMA2sh and ULK2 also occurs in
mammalian cells, as FLAG-tagged full-length ULK2 copreci-
pitates with CARMA2sh when lysates prepared from cotrans-
fected HEK293T cells were immunoprecipitated with an anti-
FLAG antibody, but not with an anti-myc control antibody
(Figure 1a). Also, transfected CARMA2sh coprecipitates
endogenous ULK2 in the human keratinocyte HaCaT cell line
(Figure 1b).
In performing these co-expression experiments, we
observed that in SDS-PAGE separations CARMA2sh
migrates as a doublet when expressed together with ULK2
in HEK293T cells, suggesting that ULK2 could promote
phosphorylation of CARMA2sh (Figure 1c, upper and lower
panels). In fact, CARMA2sh doublets disappear when lysates
prepared from cotransfected HEK293T cells were treated with
calf intestinal phosphatase (CIP) for 30 min immediately
before SDS-PAGE separation (Figure 1c, upper panel). For
instance, transfected CARMA2sh in SDS/PAGE migrates at
an higher molecular mass than that predicted from its amino
acid sequence (83.6 kDa predicted versus≈100 kDa observed
in SDS/PAGE) (Figure 1c, lower panel, lane 2). When lysates
were treated with CIP, a signal appears at ≈80 KDa (lane 4),
which corresponds to the predicted molecular mass of
CARMA2sh. The ≈80 KDa band disappears again when
lysates were treated with a mixture of phosphates inhibitors
(lanes 3 and 6), confirming that the ≈100 KDa signal includes
phosphorylated forms of CARMA2sh. Of note, co-transfection
of ULK2 with CARMA2sh further increases the molecular
mass shift of CARMA2sh (lane 5). Overall, these results
demonstrate that a consistent fraction of transfected
CARMA2sh is present in the cells in a phosphorylated form,
and that ULK2 is able to phosphorylate CARMA2sh. More-
over, as shown later in Supplementary Figure 3, CARMA2sh
doublets were not observed when CARMA2shwas expressed
together with the kinase inactive mutant ULK2K39I.21 Finally,
in a mixed beads in vitro kinase assays wt ULK2, but not
ULK2K39I, promoted a shift in the SDS/PAGE mobility of
CARMA2sh (Figure 1d). Considering altogether these results,
we concluded that ULK2 promotes, directly or indirectly,
phosphorylation of CARMA2sh.
Next, we tried to map the region of CARMA2sh phosphory-
lated by ULK2 using deletion mutants of CARMA2sh. The
results of these experiments, shown in Supplementary
Figure 1, mapped the phosphorylation site of CARMA2sh
in the linker region of the protein, within the amino acidic
stretch Asp458–Ser500, which contains 10 serine residues
and 1 threonine residue. Indeed, a construct encoding for
a deleted version of CARMA2sh lacking this region
(CARMA2shΔ458-500; predicted molecular mass 79.9 KDa),
that we generated and used later in this work, migrates at the
expected position in SDS/PAGE separations (Supplementary
Figures 3 and 4).
ULK2 represses the NF-κB-inducing activity of wt
CARMA2sh, but not that of the non-phosphorylatable
or psoriasis-linked CARMA2sh mutants. Most of the
psoriasis-linked CARMA2sh mutants enhance the transcrip-
tional activity of NF-κB,6–9,11 which catalyzes transcription of
inflammatory mediators and plays a significant role in the
progression of the disease.25 Thus, we tested the effect of
ULK2 on the NF-κB-inducing activity of CARMA2sh. Pre-
liminary experiments carried out using an NF-κB-luciferase
reporter assay and shown in Figure 2a, indicated that wt
ULK2, but not ULK2K39I, dramatically diminishes the NF-κB-
inducing activity of CARMA2sh.
Importantly, in the same assay, the NF-κB-inducing activity
of the non-phosphorylatable mutant CARMA2shΔ458-500
was not affected by ULK2 expression, suggesting that
CARMA2sh phosphorylation is necessary for ULK2 to
operate its negative control on the NF-κB-inducing activity of
CARMA2sh. Even more importantly, two of the most recurrent
psoriasis-linked mutants, CARMA2shE138A and CARMA2-
shE142G, which are both stronger activators of NF-κB
compared to wt CARMA2sh,6–8 were only slightly affected
by ULK2 expression.
ULK2 represses expression of inflammatory genes in
human keratinocytes exposed to PAMPs. Subsequently,
we investigated the negative effect of ULK2 on the NF-κB-
inducing activity of CARMA2sh in a more physiological
experimental system. Given the evidence that CARMA2sh
is predominantly expressed in the human skin,7,10 we
decided to use normal human epidermal keratinocytes
(NHEK) for a panel of experiments aimed at defining a
physiological NF-κB activation pathway dependent on
CARMA2sh and inhibited by ULK2. At this point, however,
we faced a significant issue. In fact, although it is known that
CARMA1 intervenes in the signal transduction pathway that
leads to NF-κB activation in B and T lymphocytes following
antigen receptor stimulation,12–15 and that CARMA3 controls
Table 1 Interaction of CARMA2sh with ULK2 in the yeast two-hybrid assay
Protein fused to GAL4
domain
Yeast growth on selective media
DNA binding Activating
— ULK2805–1036 −
Vector ULK2805–1036 −
FADD ULK2805–1036 −
CARMA2sh ULK2805–1036 +++
CARMA2sh — −
Yeast AH109 was transformed with CARMA2sh fused to the GAL4-activating
domain together with the indicated cDNAs fused to GAL4 DNA-binding domain.
The cDNA encoding for FADD served as a putative negative control. Interactions
were examined by yeast growth on selective media; assays were done for 10
independent transformants. Yeast colonies were scored as positive when a
growth developed within 24–36 h; a negative was scored when growth failed to
develop within 1 week
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NF-κB activation following G-coupled protein receptors
triggering in a variety of cell types,12–15 it is currently not
known from which membrane receptor(s) signaling, if any,
CARMA2sh triggers NF-κB activation. While testing a number
of different stimuli, including several inflammatory cytokines
such as TNFα and IL-1β, it has not escaped our notice that a
significant repression of inflammatory NF-κB target genes
was observed when NHEK-expressing ULK2 were exposed
to heat-killed bacterial (Escherichia coli and Staphylococcus
aureus) or fungi (Chorizanthe valida) cells (Figure 2b). Heat-
killed bacterial and fungi cells display PAMPs and activate
NF-κB upon agonistic binding to pattern recognition recep-
tors, including members of the TLRs family expressed on
human keratinocytes.26,27 Consistently with the experiments
Figure 1 ULK2 binds to and phosphorylates CARMA2sh. (a) HEK293T cells were cotransfected with a plasmid encoding for HA-tagged CARMA2sh together with a FLAG-
tagged expression vector empty or encoding for ULK2. About 24 h later, lysates were immunoprecipitated with anti-FLAG or anti-myc control antibodies and analyzed for
coprecipitating HA-CARMAsh by western blot assay. (b) HaCaT cells were transfected with either an empty plasmid or encoding for HA-tagged CARMA2sh. About 24 h later, cells
were lysed and immunoprecipitated with anti-HA or anti-myc control antibodies, and analyzed for coprecipitating endogenous ULK2 protein by western blot assay.
(c) HEK293T cells were cotransfected with a plasmid encoding for HA-tagged CARMA2sh together with an expression vector encoding for ULK2. About 24 h later, CARMA2sh
expression was analyzed by immunoblot assay probed with anti-HA. Where indicated, the cell lysate was treated with CIP (0.5 U/μg lysate) for 30 min at 37 °C and/or a mixture of
phosphatase inhibitors (i-CIP). (d) Lysates from HEK293T separately transfected with the indicated expression plasmids were immunoprecipitated and tested in a mixed beads
in vitro kinase assay as described in Material and Methods section. The slower migration in SDS/PAGE of wt ULK2 compared to ULK2K39I is due to ULK2 autophosphorylation
(data not shown)
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Figure 2 ULK2 represses the NF-κB-inducing activity of CARMA2sh. (a) HEK293T cells were transiently cotransfected with expression vectors encoding for the
indicated polypeptides, together with NF-κB-luciferase and β-galactosidase reporter vectors. About 24 h after transfection, cell lysates were prepared and luciferase activity was
measured. Data were analyzed by Student’s t-test, and a P-value ⩽ 0.05, indicated with an *, was considered significant. Data shown represent relative luciferase activity
normalized against β-galactosidase activity and are representative of at least 10 independent experiments done in triplicate. Lower panel: a fraction of the cell lysate was analyzed
by immunoblot assay to monitor protein expression. (b) NHEK were transfected with an expression vector encoding for ULK2 or GFP. About 24 h later, cells were left in PBS or
exposed to the indicated heat-killed microorganisms for 16 h, and the expression level of selected NF-κB target genes was monitored by real-time PCR. Graphs show the fold
changes respect to the GFP-transfected cells left in PBS. Data were analyzed by Student’s t-test, and a P-value ⩽ 0.05, indicated with an *, was considered significant. Data
shown are representative of at least three independent experiments done in triplicate. (c) NHEK cells were infected with lentiviral vectors encoding for shULK2 or a scramble
control sequence, and then treated and assayed as in b. Graphs show the fold changes respect to the scramble-infected cells left in PBS. Data shown are representative of at
least three independent experiments done in triplicate. Efficacy of ULK2 attenuation by shRNAs was monitored by real-time PCR and immunoblot assay. (d) NHEK were infected
with lentiviral vectors encoding for indicated shRNAs or a scramble control sequence and then treated and assayed as in (c). (e) NHEK cells were left in PBS or exposed to heat-
killed S. aureus cells for 16 h. Where indicated, the cell lysate was treated with CIP for 30 min at 37 °C and endogenous CARMA2sh expression was analyzed by
immunoblot assay
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shown in Figure 2a, short interfering (sh) RNA targeting ULK2
enhanced the expression level of these inflammatory NF-κB
target genes in NHEK exposed to the same stimuli
(Figure 2c). Thus, in human keratinocytes ULK2 regulates
NF-κB activation ensuing from PAMPs recognition, possibly
acting on the CBM complex-mediated signaling.
The CARMA2/BCL10/MALT1 complex connects PAMPs
recognition to NF-κB activation. The inhibitory effect on
NF-κB activation exerted by ULK2 in NHEK exposed to
PAMPs could be due either to an ULK2-mediated suppres-
sion of the NF-κB-inducing activity of CARMA2sh, or to an
ULK2-sensitive but CARMA2sh-independent mechanisms.
To test for this, we used shRNA to individually deplete NHEK
of the CBM complex components, id est CARMA2, BCL10
and MALT1. As shown in Figure 2d, abrogation of either
CARMA2sh or BCL10 or MALT1 significantly impairs
expression of NF-κB target genes in NHEK exposed to
PAMPs. Remarkably, NHEK exposure to heat-killed S. aureus
promotes a shift in the SDS-PAGE mobility of endogenous
CARMA2sh, which was abolished by phosphatase treatment
(Figure 2e). These data clearly indicate that in human
keratinocytes the CBM complex participates in the signal
transduction pathway that connects PAMPs recognition to
NF-κB activation. Also, together with the evidences shown
before, these experiments indicate that ULK2 negatively
regulates this pathway, whereas the two psoriasis-linked
CARMA2sh mutants tested escape such a negative control.
This observation is particularly remarkable as TLRs activa-
tion is considered to play an important role in the patho-
physiology of psoriasis.28,29
ULK2 promotes lysosomal degradation of BCL10. The
NF-κB-inducing activity of both wt- and psoriasis-linked
CARMA2sh mutants requires BCL10, as assessed by
experiments based on shRNA-mediated depletion of BCL10
Figure 2 Continued
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(Figure 3a, left panel) and disruption of the BCL10 locus
through CRISPR/Cas9/sgRNA technology in HEK293T cells
(Figure 3a, right panel). Moreover, in the BCL10-targeted cell
lines BCL10-1/CR#2 and BCL10-2/CR#2 re-introduction of a
plasmid-encoded BCL10 fully restores the NF-κB-inducing
activity of CARMA2sh (data not shown). Therefore, we
explored the possibility that ULK2 could inhibit the NF-κB-
inducing activity of CARMA2sh by regulating the expression
level of BCL10. Indeed, as shown in Figure 3b, in
HEK293T cells expression of CARMA2sh, which mimics acti-
vation of the CBM complex with consequent NF-κB activation,
results in a reduction of endogenous BCL10 protein level,
which was further accentuated by co-expressed ULK2.
BCL10 reduction was rescued by the lysosomal inhibitor
leupeptin, but not by the proteasomal inhibitor MG132
(Figure 3b upper and lower panels). Consistently, the
lysosomal inhibitor 3-methyladenine (3-MA) rescued the
inhibitory effect of ULK2 on the NF-κB-inducing activity of
CARMA2sh (Supplementary Figure 2). Reduction of endo-
genous BCL10 following CARMA2sh expression requires the
kinase activity of ULK2, as it was not observed when either
shRNA targeting ULK2 or ULK2K39I were used (Figures 3c
and d). ULK2-mediated reduction of BCL10 requires phos-
phorylation of CARMA2sh, as it was not observed when the
mutant CARMA2shΔ458-500 was used (Figure 4a).
Together with the experiments done in the presence of
lysosomal inhibitors, examination of LC3 conversion from
LC3-I to LC3-II by immunoblot assay further pointed to a
autophagic route of BCL10 triggered by wt ULK2, but not
ULK2K39I, and promoted by wt CARMA2sh but not by
CARMA2shΔ458-500 (Figure 4b). Finally, reduction of endo-
genous BCL10 was also observed in NHEK upon expression
Figure 3 ULK2 promotes degradation of BCL10. (a) Left panel: HEK293T cells infected with a lentiviral vector expressing a shRNA targeting BCL10 or a scramble sequence
were transiently cotransfected with expression vectors encoding for the indicated polypeptides, together with NF-κB-luciferase and β-galactosidase reporter vectors. About 24 h
after transfection, cell lysates were prepared and luciferase activity was measured. Data shown represent relative luciferase activity normalized against β-galactosidase activity
and are representative of at least 10 independent experiments done in triplicate. Data were analyzed by Student’s t-test, and a P-value⩽ 0.05, indicated with an *, was considered
significant. Right panel: two independent HEK293T lines (BCL10-1/CR#2 and BCL10-2/CR#2) stably harboring Cas9 and a sgRNA targeting BCL10 were used for the NF-κB
luciferase assay described before. The cell lines BCL10-1/CR#1 and BCL10-2/CR#1, harboring an unproductive BCL10 sgRNA, were used as a control. Lower panel: immunoblot
and densitometric analysis of BCL10 expression level in BCL10-targeted HEK293T cell lines. (b) HEK293T cells were transiently transfected with the indicated expression vectors
and after 24 h treated or not with lysosomal (Leupeptin, 10 μM) or proteasomal (MG132, 10 μM) inhibitors 1 h before lysis. Endogenous BCL10 expression was assessed
by immunoblot assay. Lower panel: MG132 efficacy was monitored by assessing proteasomal degradation of IκBα following TNFα stimulation (20 ng/ml for 30 min).
(c–d) HEK293T cells expressing the indicated shRNAs and/or polypeptides were assessed for endogenous BCL10 expression by western blot assay
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of wt ULK2 but not ULK2K39I, and it was rescued by the
lysosomal inhibitor 3-MA (Figures 4c and d). Thus, ULK2
negatively regulates the CBM complex signaling, most likely
by promoting lysosomal degradation of BCL10.
Psoriasis-linked CARMA2sh mutants fail to promote
BCL10 degradation. Next, we investigated for a mechanism
that would explain why CARMA2shE138A and CARMA2-
shE142G mutants elude the ULK2 negative control on NF-κB
activation. First of all, we examined whether CARMA2-
shE138A and CARMA2shE142G mutants are still able to
associate to and be phosphorylated by ULK2. The experi-
ments shown in Supplementary Figure 3 indicate that, in
transfection experiments, the non-phosphorylatable mutant
CARMA2shΔ458-500 and the psoriasis-linked CARMA2-
shE138A and CARMA2shE142G mutants are all still able
to co-immunoprecipitate with ULK2. In addition, as judged by
a shift in the SDS/PAGE mobility, both CARMA2shE138A and
CARMA2shE142G mutants appear to be phosphorylated by
ULK2 (Supplementary Figure 3). Thus, phosphorylation of
CARMA2sh by ULK2 is required but not sufficient for ULK2-
mediated inhibition of the NF-κB-inducing activity of CAR-
MA2sh. Thus, we explored the possibility that
CARMA2shE138A and CARMA2shE142G might fail to
promote degradation of BCL10. Indeed, reduction of endo-
genous BCL10 protein was not observed when the psoriasis-
linked mutants CARMA2shE138A or CARMA2shE142G
were expressed with ULK2 in NHEK (Figure 5a).
We then verified the possibility that the inability of
CARMA2shE138A and CARMA2shE142G to promote degra-
dation of BCL10 was somehow associated with their higher
capacity to activate NF-κB. For this, we tested an additional
psoriasis-linked mutant, CARMA2shR38C, which is incapable
to activate NF-κB.6 However, as shown in Supplementary
Figure 4, also CARMA2shR38C is unable to support
degradation of BCL10.
Moreover, following exposure to PAMPs, BCL10 degrada-
tion could be readily observed in mock-transfected NHEK
(Figure 5b), or NHEK-expressing wt CARMA2sh, but not
in NHEK expressing the mutants CARMA2shΔ458-500,
CARMA2shE138A or CARMA2shE142G (Figure 5b). Analy-
sis of BCL10 mRNA expression in NHEK did not reveal any
significant change upon ULK2 or CARMA2sh isoforms
expression (data not shown), confirming that ULK2-mediated
reduction of BCL10 occurs at protein level. Altogether, these
data indicate that ULK2-mediated lysosomal degradation of
Figure 4 ULK2 promotes degradation of BCL10. (a) HEK293T cells were transiently transfected with expression vectors encoding for the indicated polypeptides. About 24 h
later, cell lysates were prepared and monitored for endogenous BCL10 expression by immunoblot assay. (b) HEK293T cells were transiently transfected with expression vectors
encoding for the indicated polypeptides. About 24 h after transfection, cells were left untreated or treated with the lysosome inhibitor leupeptin (10 μM) for 1 h. Cell lysates were
then prepared and monitored for conversion of LC3-I to LC3-II by immunoblot assay. (c) NHEK were transfected with an expression vector encoding for wt ULK2 or the kinase-
dead mutant ULK2K39I. About 16 h later, cell lysates were prepared and BCL10 expression was determined by immunoblot assay. (d) Immunofluorescence analysis of BCL10 in
NHEK infected with lentiviral vectors expressing the indicated polypeptides and left in medium alone or medium supplemented with the autophagy inhibitor 3-MA (5 mM). Data
shown are representative of three independent experiments
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BCL10 represents an intrinsic homeostatic mechanism that
restricts NF-κB signaling in keratinocytes, and the psoriasis-
linked CARMA2shmutants we tested failed to promote such a
constraining mechanism.
Overall, the data shown above indicate that BCL10 is a key
regulator of the NF-κB-inducing activity of wt- and psoriasis-
associated CARMA2sh mutants. Thus, we tested whether
liposome-assisted delivery of a BCL10 inhibitory peptide30
could reduce NF-κB activation in NHEK exposed to PAMPs.
Indeed, the expression level of two monitored NF-κB target
genes was partially but significantly diminished when NHEK
were treated with a BCL10 inhibitory peptide, but not a control
peptide (Figure 6).
Discussion
In this paper we report the identification of ULK2 as a kinase
that promotes phosphorylation of CARMA2sh, very likely in
the linker region of the protein. This evidence is of particular
interest, as it is already known that phosphorylation events
occurring in the linker region of CARMA1 control its functional
activity. In lymphoid cells, PKC-mediated phosphorylation of
the linker region of CARMA1 controls NF-κB activation by
triggering a shift from an inactive to an active CARMA1
conformer.31–33 Thus, a CARMA1 mutant in which Ser552 is
mutated fails to mediate TCR-induced NF-κB activation in
CARMA1-deficient T cells, whereas deletion of the linker
results in constitutive, receptor- and PKC-independent
NF-κB activation. As a consequence, constitutive activation
of NF-κB driven bymutations in the linker region of CARMA1 is
considered to be the molecular basis of some B-cell
malignancies.34,35 We find now that phosphorylation of the
linker region in CARMA2sh is somehow also required to
trigger the subsequent lysosomal degradation of BCL10, that
is, as a signal necessary to terminate CBM complex-mediated
activation of NF-κB. Further studies are needed to verify if
such a regulatory mechanism applies for CARMA1 as well, as
lysosomal degradation of BCL10 has been proposed as an
NF-κB signal-off mechanism in activated lymphocytes.17–19
Our prediction would be that the constitutive NF-κB activity
resulting from the linker mutants of CARMA1 also derives from
failure to degradate BCL10. In fact, as the NF-κB-inducing
activity of CARMA1 requires BCL10, either these mutants do
not support degradation of BCL10, or, vice versa, they would
be unable to produce constitutive NF-κB activation.
We also show that at least three CARMA2sh mutants
associated with genetic psoriasis fail to promote degradation
of BCL10, despite being phosphorylated by ULK2. Thus, our
data indicate that although phosphorylation of CARMA2sh is a
necessary signal to initiate degradation of BCL10, possibly
further components must be recruited for selective BCL10
degradation to take place.Much of the information available on
ULK2 comes from studies conducted on its close family
member ULK1, which represents a central component of the
Figure 5 Psoriasis-linked CARMA2sh mutants fail to promote BCL10 degradation. (a) NHEK cells were transiently transfected with expression vectors encoding for the
indicated polypeptides and analyzed for endogenous BCL10 expression by immunoblot assay. (b) NHEK infected with retroviral vectors encoding for the indicated polypeptides
were exposed to the indicated stimuli for 4 h and the expression level of BCL10 was determined by immunoblot experiments. Data shown are representative of three independent
experiments done in triplicate
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autophagy regulatory complex.23,36 Although derived from
studies on ULK1, these data are perfectly consistent with the
evidence shown in our work, pointing to an essential role for
ULK2 in triggering lysosomal degradation of BCL10 as a
mechanism for quenching NF-κB-activating stimuli conveyed
through the CBM complex.
We also demonstrated that a CBM complex comprising
CARMA2sh in human keratinocytes transduces NF-κB signal-
ing upon PAMPs recognition on the cell membrane. Evidence
in this direction, at least for BCL10 and MALT1, already
exist in the literature;20–22 however, our discovery made in
keratinocytes is particularly evocative, either for the historical
association between the onset of psoriasis and bacterial
infections, either for more recent associations between
genetic variants of TLR4, a major player in PAMPs recognition
and psoriasis.37–39 Also, this observation is consistent with
three recent papers published while this work was in
preparation, showing that the proteolytic activity of MALT1 is
required for CARMA2sh-induced activation of NF-κB.40–42
In conclusion, here we have shown that the CBM complex
has an essential role in the activation of the NF-κB pathway
following human keratinocytes exposure to PAMPs, and that
ULK2-mediated degradation of BCL10 represents a mechan-
ism through which this signaling is turned off. Degradation of
BCL10 by ULK2 requires phosphorylation of CARMA2sh, and
is prevented by several psoriasis-linked CARMA2sh muta-
tions. Thus, the inflammatory phenotype observed in psoriatic
skin may result from unrestrained NF-κB signaling due to
deficiency of lysosomal BCL10 degradation. Certainly, our
data do not exclude the possibility that in addition to the
lysosomal pathway also other posttranscriptional mechan-
isms may contribute to degradation of BCL10. Indeed, as we
show in the present work, targeting of BCL10 may represent a
novel approach for the treatment of this debilitating disease.
Materials and Methods
Two-hybrid screening. The two-hybrid screening was performed using the
Matchmaker system (Clontech, Mountain View, CA, USA) as previously
described.43 Briefly, yeast strain AH109 GAL4− /− was first transformed with
pGBKT7 plasmids carrying the CARMA2sh cDNA bait fused with DBD of GAL4
using lithium acetate/PEG 3000 procedure. Transformant colonies were selected on
synthetic dropout plates lacking tryptophan. Expression of bait fusion proteins was
assessed by immunoblot analysis. For library screening, yeast AH109 expressing
GAL4DBD-CARMA2sh was transformed with a human fetal brain cDNA library
cloned in pACT2 vector (Clontech) in fusion with GAL4TAD. About 2 × 106 clones
were screened for interaction with GAL4DBD-CARMA2sh using selective growth on
minimal medium lacking nutrients whose biosynthesis is mediated by genes under
control of the GAL4 transcriptional activity.
Cell culture, plasmids and antibodies. HEK293T and HaCaT cells were
obtained from ATCC and cultured in Dulbecco's modified Eagle's medium
supplemented with 10% FCS. NHEK were purchased from Lonza (Basel,
Switzerland) and cultured according to the provided instructions. HEK293T were
transfected by calcium phosphate precipitation; NHEK were transfected using
DreamFect Gold Transfection Reagent (OZ Biosciences, Marseille, France)
according to the manufacturer’s instruction. HaCaT were transfected with
Lipofectamine 3000. Retroviral infections were carried out as previously
described.44 CARMA2sh and ULK2 mutants were generated through PCR-
mediated methods and confirmed by sequencing. Lentiviral vectors expressing
shRNAs targeting ULK2 were a gift from Dr. R Shaw (Addgene plasmid #27634,
Cambridge, MA, USA). The list of primers and oligos used for this study is shown in
the Supplementary Figure 5.
Sources of antisera and monoclonal antibodies were the following: anti-FLAG, anti-
β-actin, anti-ULK2, Sigma-Aldrich (St. Louis, MO, USA); anti-CARMA1, Santa Cruz
Biotechnology (Dallas, TX, USA). Antisera against BCL10 and CARMA2 were
generated in our laboratory and were previously described.11,45
To disrupt BCL10 gene, a CRISPR/Cas9/single guide (sg) RNA system was
designed.46 The sg sequences were cloned into LentiCRISPRv2 containing a Cas9
expression cassette (Addgene) and transduced into HEK293T cells. After puromycin
(3 μg/ml) selection, cells stably expressing Cas9/BCL10 sgRNA were isolated.
The efficiency of BCL10 knockout was determined by immunoblotting.
Immunoblot analysis and coprecipitation. Cell lysates were made in
lysis buffer (150 mM NaCl, 50 mM Tris, pH 7.2, 1% NP40, 2 mM EDTA and a
Figure 6 (a) BCL10 inhibitory peptide represses NF-κB signaling upon PAMPs recognition in NHEK. NHEK were liposome-delivered with a BCL10 inhibitory peptide
(i-BCL10) or a control scrambled peptide (c-BCL10) and exposed to PAMPs for 24 h. Expression level of the indicated NF-κB responsive genes was determined by real-time PCR.
Data shown are representative of six independent experiments done in triplicate. Right panel: FITC-conjugated i-BCL10 peptide was used to monitor delivery efficiency (≅50%).
(b) The expression levels of BCL10, MALT1 and CARMA2sh in NHEK left untreated or i-BCL10-delivered were assessed by western blot
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mixture of protease inhibitors). Proteins were separated by SDS-PAGE, transferred
onto nitrocellulose membrane and incubated with primary antibodies followed by
horseradish peroxidase-conjugated secondary antibodies (Amersham Biosciences,
Piscataway, NJ, USA). Blots were developed using the ECL system (Amersham
Biosciences). For coimmunoprecipitation experiments, cells were lysed in lysis buffer
and immunocomplexes were bound to protein A/G (Roche, Basel, Switzerland),
resolved by SDS-PAGE and analyzed by immunoblot assay. All immunoblots were
done at least three times using different biological material as sources. Phosphatase
Inhibitor Cocktail was purchased from Sigma and used according to the instructions
provided.
Luciferase assay. To assess for NF-κB activation state, HEK293T cells were
transfected with the indicated plasmidic DNAs together with pNF-κB-luc (Clontech)
in 6-well plates. Twenty-four hours after transfection, luciferase activity was
determined with Luciferase Assay System (Promega, Madison, WI, USA). Plasmids
expressing RSV-β-galactosidase or TK-Renilla were used in transfection mixtures in
order to normalize for efficiency of transfection.
Mixed beads in vitro kinase assay. HEK293T cells, separately transfected
with plasmids encoding for CARMA2 polypeptides and wild-type or mutant ULK2, were
lysed in ice-cold TNTE buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 0,3% (vol/vol) Triton
X-100, 5 mM EDTA) containing complete protease inhibitor cocktail (Roche), 25 mM β-
glycerophosphate, 1 mM sodium orthovanadate, 30 nM okadaic acid, 2 mM sodium
pyrophosphate. Lysates cleared by centrifugation were incubated with anti-FLAG
monoclonal M2 antibody (Sigma Aldrich) for 1 h at room temperature and then washed
three times with TNTE buffer. Immunoprecipitates were further washed once with
kinase reaction buffer (KRB) (20 mM HEPES, pH 7.5, 20 mM MgCl2, 25 mM β-
glycerophosphate, 2 mM DTT, 100 μM sodium orthovanadate and 30 nM okadaic
acid) and then mixed and incubated at a final volume of 20 μl in KRB containing 20 μM
ATP at 30 °C for 30 min. Reactions were stopped with the addition of 3% SDS sample
buffer during heating at 65 °C for 5 min. Mixed beads reaction product were resolved
by SDS-PAGE and analyzed by immunoblot assay.
Real-time PCR. Total RNA was isolated from cells or tissues using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA). The reverse transcriptase reaction was performed
using 1 μg of total RNA in a 20 μl reaction and 1 μl of the resulting cDNA was used in
the subsequent amplification step along with 300 nM of each primer. The geometric
mean values of β-actin and succinyl-CoA synthetase β-subunit fragment were used as
normalization factors. The relative transcription level was calculated by using the ΔΔCt
method. Real-time PCR reactions were performed in triplicate by using the SYBR
Green PCR Master Mix (Qiagen, Hilden, Germany) in a 7900HT system (Applied
Biosystems, Foster City, CA, USA).
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